Akebia (AKBA) Therapeutics announced multiple positive business updates. As of January, Vafseo tablets are available in the U.S. for adult patients with anemia due to chronic kidney disease on ...

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the ...

CAMBRIDGE, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney ...

Colin Kellaher, Dow Jones Newswires An FDA decision looms for Akebia Therapeutics and its proposed vadadustat treatment for anemia due to chronic kidney disease in adults on dialysis.

Analyst Ed Arce of H.C. Wainwright maintained a Buy rating on Akebia Therapeutics (AKBA – Research Report), retaining the price target of $7.50. Discover outperforming stocks and invest smarter ...

The FDA has approved Akebia Therapeutics’ vadadustat as a treatment for anaemia caused by chronic kidney disease (CKD) in dialysis patients, becoming the first rival to GSK’s Jesduvroq.

CAMBRIDGE, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, ...

On Tuesday, H.C. Wainwright maintained a Buy rating on Akebia Therapeutics (NASDAQ:AKBA) stock with a steady price target of $7.50, significantly above the current trading price of $1.88.